Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Identifying barriers to immunotherapy access for triple-negative breast cancer: A qualitative analysis of interviews with medical oncologists.

Created on 27 Oct 2026

Authors

Devika R Jutagir, Adriana Espinosa, Melissa Lopez, Maria Claros, Taisha Gomez, Jaime Gilliland, Tiffany A Traina, Bert Petersen, Francesca Gany

Published in

PloS one. Volume 21. Issue 10. Pages e0361021. Epub Oct 26, 2026.

Abstract

Immune checkpoint inhibitors, a type of immunotherapy, show promise in treating triple-negative breast cancer (TNBC). Although TNBC is more prevalent among Black and Hispanic women, they are less likely than non-Hispanic White women to be treated with immunotherapy. To date, no studies have explored the reasons underlying these disparities in the use of immunotherapy. This information is crucial for the development of targeted interventions that mitigate these disparities and accordingly address TNBC-related inequities among Black and Hispanic women. The aim of this study is to qualitatively identify medical oncologists' perspectives of barriers to immunotherapy access among patients with TNBC.
Using the Consolidated Framework for Implementation Research, between May 29, 2020 and September 23, 2022, we conducted semi-structured interviews until thematic saturation with 15 medical oncologists treating New York City metropolitan area patients with breast cancer. We used inductive content analysis to examine the interviews and identify themes corresponding to barriers to access to TNBC immunotherapy.
The following five overarching themes emerged: (1) Mixed public perceptions about immunotherapy safety and efficacy, (2) Two-tier systems of care, (3) Timely initiation of immunotherapy, (4) Lack of dissemination of best practice guidelines leads to lack of adoption of standard of care, and (5) Side effect profile impacts use and continuation of immunotherapy.
Large-scale studies quantifying the effect of these barriers on access to TNBC immunotherapy are needed to determine cause and inform effective interventions promoting equal access to all patients with TNBC.

PMID:
42932373
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement